Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Herve Souchet, Lois Kelly, Johanna Merlin, Michelle Marchal, Remy Castellano, Emmanuelle Josselin, Hélène Pasquer, Lina Benajiba, Alexandre Puissant, Oleksandr Koniev, Yves Collette, Coralie Belanger, Olivier Hermine, Renato C Monteiro, Pierre Launay
Innovative strategies to enhance efficacy and overcome drug resistance in hematologic cancers such as antibody-drug conjugates (ADCs) have shifted the paradigm of conventional care by delivering promising outcomes in cancer therapies with a significant reduction in the risk of relapse. The transferrin receptor 1, CD71, known to be overexpressed in malignant cells, is considered a potent anti-tumoral target. Therefore, we have developed an anti-CD71 ADC, INA03, a humanized antibody conjugated to the monomethyl auristatin E (MMAE) through a 3-arylpropiolonitrile-valine-citruline linker...
April 20, 2024: Molecular Cancer Therapeutics